Venetoclax For The Treatment of Translocation AL Amyloidosis

Venetoclax is a B cell lymphoma 2 (BCL-2) inhibitor active in multiple myeloma, particularly those harboring t(11;14) associated with high BCL-2 expression. Approximately 50% of patients with immunoglobulin light chain (AL) amyloidosis have t (11;14), making venetoclax a suitable agent to consider in this rare disease. We aimed to identify the safety and efficacy of venetoclax in patients with AL amyloidosis.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 30, 2019 Category: Hematology Authors: M Hasib Sidiqi, Abdullah S. Al Saleh, Nelson Leung, Mohammed Aljama, Dragan Jevremovic, Wilson Gonsalves, Francis Buadi, Taxiarchis Kourelis, Rahma Warsame, Eli Muchtar, Miriam Hobbs, Martha Lacy, David Dingli, Ronald Go, Suzanne Hayman, S.Vincent Rajkuma Source Type: research